Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached

For patients with diabetes who are also taking insulin or sulfonylureas, there is an increased risk of hypoglycaemia
Storage Conditions: Store refrigerated at 28 C
Als Tee oder Gemsegericht genossen, kann Bittermelone somit zu Recht als natrlicher Stoffwechselbooster gelten, der eng mit unserem Darm-Mikrobiom und den Inkretinhormonen zusammenspielt
Many clients use a B12 shot between IV visits, or combine the two
Its global cultivation is extensive, positioning it as one of the leading crops in yield and land area, ranking fourth after rice, maize, and wheat